The Hong Kong pharmaceutical sector continued to decline, with Shijiazhuang Pharmaceutical Group (01093.HK) falling by more than 5%, 3SBio (01530.HK) falling by more than 4%, and Hengrui Medicine (01276.HK), Innovent Biologics (02096.HK) and others following suit.